EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

Lewington S(2002)Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-1913

Clarke R(2004)High prevalence and poor control of hypertension in primary care: cross-sectional study J Hypertens 22 479-486

Qizilbash N(2011)In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies J Pharmacol Exp Ther 336 801-808

Peto R(1996)Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres J Med Chem 39 5228-5235

Collins R(1993)Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist Biochem Pharmacol 46 311-318

Sharma AM(2011)Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 413-420

Wittchen HU(2011)Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring J Clin Hypertens (Greenwich) 13 467-472

Kirch W(2011)The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure J Clin Hypertens (Greenwich) 13 81-88

Pittrow D(2012)Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study Hypertens Res 35 552-558

Ritz E(2011)Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker P T 36 634-640

Lewington S(2002)Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-1913

Clarke R(2004)High prevalence and poor control of hypertension in primary care: cross-sectional study J Hypertens 22 479-486

Qizilbash N(2011)In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies J Pharmacol Exp Ther 336 801-808

Peto R(1996)Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres J Med Chem 39 5228-5235

Collins R(1993)Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist Biochem Pharmacol 46 311-318

Sharma AM(2011)Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 413-420

Wittchen HU(2011)Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring J Clin Hypertens (Greenwich) 13 467-472

Kirch W(2011)The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure J Clin Hypertens (Greenwich) 13 81-88

Pittrow D(2012)Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study Hypertens Res 35 552-558

Ritz E(2011)Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker P T 36 634-640